Poll Results of the Annual General Meeting Held on 31 May 2024

First in China: BLA for Boan’s Dulaglutide Injection Accepted

Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for its Dul...

Acceptance of BLA in China for Dulaglutide Injection (BA5101)

Boan’s Boluojia® (Denosumab) Approved for Marketing in China

Boan Biotech today announced that Boluojia®, a denosumab injection (120mg) developed by the company, has been approved for marketing by China’s National Medical Products Administration (NMPA) fo...

Denosumab Injection (Boluojia) for Oncology Indications Approved for Marketing by NMPA

Monthly Return of Equity Issuer on Movements in Securities for The Month Ended 30 April 2024

Form of Proxy for Use at Annual General Meeting to Be Held on 31 May 2024 (Applicable to Holders of H Shares)

Notice of Annual General Meeting

(1) 2023 Report of The Board of Directors (2) 2023 Report of The Board of Supervisors (3) 2023 Annual Report (4) Proposed Re-Election of Directors of The Second Session of The Board (5) Proposed Re-Election of Shareholder Representative Supervisors of The

2023 Environmental, Social and Governance Report